Asa development strategies: investing in research

ASAlaser considers research an ethical pillar and allocating a budget to implement studies in order to define new therapeutic methods and evolved technological systems an undertaking it has been committed to since its birth. One single objective: to offer patients suffering from painful issues to the musculo-skeletal apparatus a speedy rehabilitation and a newfound motor efficiency. This is also confirmed by the numbers. Where in 2016 the Company allocated approximately 1,200,000 Euro (13.5% of the turnover) to research, the first semester of 2017 outlines a growth trend: 675,000 Euro, equal to 13.1% of the turnover.

<<Research is part of our identity -  explains Lucio Zaghetto, the ASAlaser Scientific & Educational Director,  - and as such it undergoes a continuous evolution marked by some stages, such as the 2007 collaboration agreement with the then Physiopathology Clinic Department of the University of Florence (now Department of Experimental and Clinical Biomedical Sciences "Mario Serio") and the official presentation of the Joint ASAcampus Laboratory between the Company and the University of Florence in 2009>>. A path marked by carrying out more than 100 scientific studies supervised by the Research Division of ASAlaser, of which 24 were the direct work of ASAcampus. <<With the creation of the Joint Laboratory – explains Doctor Monica Monici, in charge of ASAcampus – we began a virtuous path during which, in parallel with clinical trials, in-depth research on light-tissue interaction and on cellular and molecular mechanisms constituting the basis of the systemic effects of laser therapies, were undertaken. Such research gives rise to a continuous progress of the therapeutic devices and protocols, resulting in a more targeted and effective therapy application>>.

The Company however has gone further, creating the scientific magazine Energy For Health which is functional to disseminating scientific knowledge and to culturally promoting laser therapy and magnetotherapy by presenting the results of basic research and clinical trials carried out both in Italy and abroad. Now in its sixteenth issue, the magazine represents an important item of the Company’s scientific projects which are once again aimed at implementing basic and clinical research, lasting on average 2-3 years, for 2018. The ASAcampus researchers will not only continue to work on issues such as pain, inflammation and tissue regeneration, developed through collaborations in several European countries, the United States and China, but will also be involved in national and international research projects, supported by prestigious bodies such as the Italian and European Space Agencies.